Floatz logo

Cpx-351

Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia

Children's Oncology GroupPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

26 Active assets in the Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Princess Maxima Center for Pediatric Oncology
Phase 1/2CCC
OBI 3424
SWOG Cancer Research Network
Phase 1/2CCC
Nelarabine
M.D. Anderson Cancer Center
Phase 1/2CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 1/2CCC
PEGASPARGASE
M.D. Anderson Cancer Center
Phase 1/2CCC

View all 34 →

Same molecule, other indications

Cpx-351 is also rated in:

therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
BB
Indicative ·
67 / 100
View asset →
Secondary Acute Myeloid LeukemiaDormant
BB
Indicative ·
67 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →